{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:48:05Z","timestamp":1740178085573,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Helsinn Healthcare SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s41669-022-00326-6","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T09:02:36Z","timestamp":1645261356000},"page":"595-603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms"],"prefix":"10.1007","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0092-5970","authenticated-orcid":false,"given":"Michela","family":"Meregaglia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Tarricone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,19]]},"reference":[{"key":"326_CR1","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/CMAR.S138661","volume":"11","author":"D Denis","year":"2019","unstructured":"Denis D, Beneton N, Laribi K, Maillard H. Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel. Cancer Manag Res. 2019;11:2241\u201351.","journal-title":"Cancer Manag Res."},{"issue":"9","key":"326_CR2","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.6004\/jnccn.2014.0125","volume":"12","author":"AD Zelenetz","year":"2014","unstructured":"Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. National comprehensive cancer network. Non-Hodgkin\u2019s lymphomas, version 4.2014. J Natl Compr Canc Netw. 2014;12(9):1282\u2013303.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"326_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1365-2133.2008.08992.x","volume":"160","author":"F Sampogna","year":"2009","unstructured":"Sampogna F, Frontani M, Baliva G, Lombardo GA, Alvetreti G, Di Pietro C, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol. 2009;160(4):815\u201322.","journal-title":"Br J Dermatol"},{"issue":"1","key":"326_CR4","doi-asserted-by":"publisher","first-page":"e11302","DOI":"10.2196\/11302","volume":"21","author":"S McCaffrey","year":"2019","unstructured":"McCaffrey S, Black RA, Nagao M, Sepassi M, Sharma G, Thornton S, et al. Measurement of quality of life in patients with mycosis fungoides\/s\u00e9zary syndrome cutaneous T-cell lymphoma: development of an electronic instrument. J Med Internet Res. 2019;21(1):e11302.","journal-title":"J Med Internet Res"},{"issue":"3","key":"326_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"326_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","volume":"30","author":"MM Chren","year":"2012","unstructured":"Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30(2):231\u20136 (xiii).","journal-title":"Dermatol Clin"},{"issue":"5","key":"326_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2340\/00015555-1265","volume":"92","author":"A Reich","year":"2012","unstructured":"Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92(5):497\u2013501.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"326_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaad.2008.04.006","volume":"59","author":"NS Desai","year":"2008","unstructured":"Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol. 2008;59(2):234\u201344.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"326_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","volume":"162","author":"S Elman","year":"2010","unstructured":"Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587\u201393.","journal-title":"Br J Dermatol"},{"issue":"1","key":"326_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jval.2012.10.010","volume":"16","author":"L Longworth","year":"2013","unstructured":"Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16(1):202\u201310.","journal-title":"Value Health."},{"issue":"Suppl 1","key":"326_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40273-017-0548-7","volume":"35","author":"R Ara","year":"2017","unstructured":"Ara R, Rowen D, Mukuria C. The use of mapping to estimate health state utility values. Pharmacoeconomics. 2017;35(Suppl 1):57\u201366.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"326_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","volume":"149","author":"SR Lessin","year":"2013","unstructured":"Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25\u201332.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"326_CR13","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jaad.2019.12.070","volume":"83","author":"EJ Kim","year":"2020","unstructured":"Kim EJ, Geskin L, Guitart J, Querfeld C, Girardi M, Musiek A, et al. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study. J Am Acad Dermatol. 2020;83(3):928\u201330. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.070.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"326_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12955-018-0857-3","volume":"16","author":"H Dakin","year":"2018","unstructured":"Dakin H, Abel L, Burns R, Yang Y. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement. Health Qual Life Outcomes. 2018;16(1):31.","journal-title":"Health Qual Life Outcomes"},{"key":"326_CR15","unstructured":"HERC database of mapping studies, Version 7.0 (last updated 24th April 2019). http:\/\/www.herc.ox.ac.uk\/downloads\/herc-database-of-mapping-studies. Accessed 13 Mar 2020."},{"issue":"Suppl 1","key":"326_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40273-017-0545-x","volume":"35","author":"J Brazier","year":"2017","unstructured":"Brazier J, Ara R, Rowen D, Chevrou-Severac H. A review of generic preference-based measures for use in cost-effectiveness models. Pharmacoeconomics. 2017;35(Suppl 1):21\u201331.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"326_CR17","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/jep.12711","volume":"23","author":"SY Park","year":"2017","unstructured":"Park SY, Park EJ, Suh HS, Ha D, Lee E-K. Development of a transformation model to derive general population-based utility: mapping the pruritus-visual analog scale (VAS) to the EQ-5D utility. J Eval Clin Pract. 2017;23(4):755\u201361.","journal-title":"J Eval Clin Pract"},{"issue":"10","key":"326_CR18","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.joca.2017.05.022","volume":"25","author":"L Trenaman","year":"2017","unstructured":"Trenaman L, Stacey D, Bryan S, Taljaard M, Hawker G, Dervin G, et al. Decision aids for patients considering total joint replacement: a cost-effectiveness analysis alongside a randomised controlled trial. Osteoarthr Cartil. 2017;25(10):1615\u201322.","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"326_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ygyno.2012.10.024","volume":"128","author":"LM Hess","year":"2013","unstructured":"Hess LM, Brady WE, Havrilesky LJ, Cohn DE, Monk BJ, Wenzel L, et al. Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;128(2):175\u201380.","journal-title":"Gynecol Oncol"},{"key":"326_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev.publhealth.23.100901.140546","volume":"23","author":"T Lumley","year":"2002","unstructured":"Lumley T, Diehr P, Emerson S, Chen L. The importance of the normality assumption in large public health data sets. Annu Rev Public Health. 2002;23:151\u201369.","journal-title":"Annu Rev Public Health"},{"issue":"Suppl 1","key":"326_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10198-019-01069-8","volume":"20","author":"Z Zrubka","year":"2019","unstructured":"Zrubka Z, Beretzky Z, Hermann Z, Brodszky V, Gul\u00e1csi L, Rencz F, et al. A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. Eur J Health Econ. 2019;20(Suppl 1):119\u201332.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"326_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1087-0024.2003.09112.x","volume":"9","author":"SC Chen","year":"2004","unstructured":"Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, Sexton SA, et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc. 2004;9(2):160\u20138.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"11","key":"326_CR23","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/ijd.14132","volume":"57","author":"HM Holahan","year":"2018","unstructured":"Holahan HM, Farah RS, Fitz S, Mott SL, Ferguson NN, McKillip J, et al. Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol. 2018;57(11):1314\u20139.","journal-title":"Int J Dermatol"},{"issue":"1","key":"326_CR24","first-page":"190","volume":"182","author":"YR Semenov","year":"2020","unstructured":"Semenov YR, Rosenberg AR, Herbosa C, Mehta-Shah N, Musiek AC. Health-related quality of life and economic implications of cutaneous T-cell lymphoma. Br J Dermatol. 2020;182(1):190\u20136.","journal-title":"Br J Dermatol"},{"key":"326_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejca.2020.04.010","volume":"133","author":"R Dummer","year":"2020","unstructured":"Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, et al. Patient-reported quality of life in patients with relapsed\/refractory cutaneous T-cell lymphoma: results from the randomised phase III ALCANZA study. Eur J Cancer. 2020;133:120\u201330.","journal-title":"Eur J Cancer"},{"issue":"5","key":"326_CR26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/jdv.16021","volume":"34","author":"CM Herbosa","year":"2020","unstructured":"Herbosa CM, Semenov YR, Rosenberg AR, Mehta-Shah N, Musiek AC. Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and S\u00e9zary syndrome: comparison of generic and dermatology-specific instruments. J Eur Acad Dermatol Venereol. 2020;34(5):995\u20131003.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"326_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12955-017-0711-z","volume":"15","author":"Y Meng","year":"2017","unstructured":"Meng Y, McCarthy G, Berthon A, Dinet J. Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours \u2013 an analysis based on the CLARINET study. Health Qual Life Outcomes. 2017;15(1):131.","journal-title":"Health Qual Life Outcomes"},{"key":"326_CR28","unstructured":"Orphanet Report Series. Prevalence of rare diseases: Bibliographic data. Number 2\u2014June 2018. http:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf. Accessed 27 Mar 2020."},{"issue":"2","key":"326_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.healthpol.2018.12.003","volume":"123","author":"O Efthymiadou","year":"2019","unstructured":"Efthymiadou O, Mossman J, Kanavos P. Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients. Health Policy. 2019;123(2):159\u201365.","journal-title":"Health Policy"},{"issue":"6","key":"326_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40273-020-00897-4","volume":"38","author":"M Meregaglia","year":"2020","unstructured":"Meregaglia M, Whittal A, Nicod E, Drummond M. \u201cMapping\u201d health state utility values from non-preference-based measures: a systematic literature review in rare diseases. Pharmacoeconomics. 2020;38(6):557\u201374.","journal-title":"Pharmacoeconomics"},{"key":"326_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7525-12-35","volume":"12","author":"I Proskorovsky","year":"2014","unstructured":"Proskorovsky I, Lewis P, Williams CD, Jordan K, Kyriakou C, Ishak J, et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes. 2014;12:35.","journal-title":"Health Qual Life Outcomes"},{"key":"326_CR32","doi-asserted-by":"publisher","first-page":"b2688","DOI":"10.1136\/bmj.b2688","volume":"339","author":"D Arnold","year":"2009","unstructured":"Arnold D, Girling A, Stevens A, Lilford R. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis. BMJ. 2009;339:b2688.","journal-title":"BMJ"},{"issue":"8","key":"326_CR33","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jval.2012.08.2201","volume":"15","author":"D Rowen","year":"2012","unstructured":"Rowen D, Young T, Brazier J, Gaugris S. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer. Value Health. 2012;15(8):1059\u201368.","journal-title":"Value Health."},{"key":"326_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12955-014-0196-y","volume":"13","author":"DT Arnold","year":"2015","unstructured":"Arnold DT, Rowen D, Versteegh MM, Morley A, Hooper CE, Maskell NA. Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma. Health Qual Life Outcomes. 2015;13:6.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"326_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11136-015-1082-8","volume":"25","author":"S Petrou","year":"2016","unstructured":"Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. Qual Life Res. 2016;25(2):275\u201381.","journal-title":"Qual Life Res"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00326-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-022-00326-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00326-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T07:52:28Z","timestamp":1657785148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-022-00326-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,19]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["326"],"URL":"https:\/\/doi.org\/10.1007\/s41669-022-00326-6","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"type":"print","value":"2509-4262"},{"type":"electronic","value":"2509-4254"}],"subject":[],"published":{"date-parts":[[2022,2,19]]},"assertion":[{"value":"25 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study were used under license for the current study and are therefore not publicly available. However, data are available from the authors upon reasonable request and with permission of Helsinn Healthcare SA. Code availability is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Michela Meregaglia and Rosanna Tarricone declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was supported by an unrestricted grant from Helsinn Healthcare SA.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Both authors contributed to the study conception and design, and MM performed the data analysis. The first draft of the manuscript was written by MM and was revised, commented on and integrated by RT. Both authors read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}